This webinar will feature members of Sidley’s Private Equity and Food, Drug and Medical Device Regulatory teams in conversation with a GC from the healthcare technology industry to consider how private equity investors should interpret the FDA’s response to the COVID-19 pandemic. We will explore:
- how COVID-19 motivated the FDA to quickly issue guidance on a range of topics
- emergency use authorizations
- new ways to utilize real-world evidence and alternative trial designs
- implications for regulated industry, including clinical study, pathways to approval and potential exclusivity
Speakers:
Lori Bennett
General Counsel
Aetion, Inc.
Geoffrey W. Levin
Partner, Private Equity
Sidley Austin LLP
Emily Marden
Counsel, Food, Drug and Medical Device Regulatory
Sidley Austin LLP
Rebecca K. Wood
Partner, Food, Drug and Medical Device Regulatory
Sidley Austin LLP
ABOUT THE SERIES
This is the third webinar in a series designed to discuss topics relevant to private equity investors in life sciences and healthcare. Past sessions have covered the boom in telehealth (view recording here) as well as securing the drug supply chain (view recording here). Information about future sessions will be shared at a later date.
